Efficacy of Low-Dose Trimethoprim/Sulfamethoxazole for the Treatment of Pneumocystis jirovecii Pneumonia in Deceased Donor Kidney Recipients

References

• Struijk GH, Gijsen AF, Yong SL, et al. Risk of Pneumocystis jiroveci pneumonia in patients long after renal transplantation. Nephrol Dial Transplant. 2011;26(10):3391–3398. doi:10.1093/ndt/gfr04821385859
   PubMed Web of Science ®Google Scholar
• Rodriguez M, Fishman JA. Prevention of infection due to Pneumocystis spp. in human immunodeficiency virus-negative immunocompromised patients. Clin Microbiol Rev. 2004;17(4):770–782, table of contents. doi:10.1128/cmr.17.4.770-782.200415489347
   PubMed Web of Science ®Google Scholar
• Neff RT, Jindal RM, Yoo DY, Hurst FP, Agodoa LY, Abbott KC. Analysis of USRDS: incidence and risk factors for Pneumocystis jiroveci pneumonia. Transplantation. 2009;88(1):135–141. doi:10.1097/TP.0b013e3181aad25619584693
   PubMed Web of Science ®Google Scholar
• Eitner F, Hauser IA, Rettkowski O, et al. Risk factors for Pneumocystis jiroveci pneumonia (PcP) in renal transplant recipients. Nephrol Dial Transplant. 2011;26(6):2013–2017. doi:10.1093/ndt/gfq68921071545
   PubMed Web of Science ®Google Scholar
• Thomas CF, Limper AH. Pneumocystis pneumonia. N Engl J Med. 2004;350(24):2487–2498. doi:10.1056/NEJMra03258815190141
   PubMed Web of Science ®Google Scholar
• Stern A, Green H, Paul M, Vidal L, Leibovici L. Prophylaxis for Pneumocystis pneumonia (PCP) in non-HIV immunocompromised patients. Cochrane Database Syst Rev. 2014;2014(10):Cd005590. doi:10.1002/14651858.CD005590.pub3
   PubMed Web of Science ®Google Scholar
• European best practice guidelines for renal transplantation. Section IV: long-term management of the transplant recipient. IV.7.1 late infections. Pneumocystis carinii pneumonia. Nephrol Dial Transplant. 2002;17(Suppl 4):36–39. doi:10.1093/ndt/17.suppl_4.36-a12091642
   PubMedGoogle Scholar
• Goto N, Futamura K, Okada M, et al. Management of Pneumocystis jirovecii pneumonia in kidney transplantation to prevent further outbreak. Clin Med Insights Circ Respir Pulm Med. 2015;9(Suppl 1):81–90. doi:10.4137/ccrpm.s2331726609250
   PubMedGoogle Scholar
• Li T, Shi J, Xu F, Xu X. Clinical characteristics of pneumocystis pneumonia after parental renal transplantation. Infect Drug Resist. 2020;13:81–88. doi:10.2147/idr.s23403932021322
   PubMed Web of Science ®Google Scholar
• Tu GW, Ju MJ, Xu M, et al. Combination of caspofungin and low-dose trimethoprim/sulfamethoxazole for the treatment of severe Pneumocystis jirovecii pneumonia in renal transplant recipients. Nephrology (Carlton). 2013;18(11):736–742. doi:10.1111/nep.1213324571744
   PubMed Web of Science ®Google Scholar
• Chai YX, Ji JL, Li SJ, et al. Efficacy of anti-T-lymphocyte globulin-Fresenius as an induction agent in deceased-donor renal transplantation: a cohort study. Exp Ther Med. 2020;19(3):2384–2390. doi:10.3892/etm.2020.845132104307
   PubMed Web of Science ®Google Scholar
• Kasiske BL, Zeier MG, Chapman JR, et al. KDIGO clinical practice guideline for the care of kidney transplant recipients: a summary. Kidney Int. 2010;77(4):299–311. doi:10.1038/ki.2009.37719847156
   PubMed Web of Science ®Google Scholar
• Chadban SJ, Barraclough KA, Campbell SB, et al. KHA-CARI guideline: KHA-CARI adaptation of the KDIGO clinical practice guideline for the care of kidney transplant recipients. Nephrology (Carlton). 2012;17(3):204–214. doi:10.1111/j.1440-1797.2011.01559.x22212251
   PubMed Web of Science ®Google Scholar
• Borstnar S, Lindic J, Tomazic J, et al. Pneumocystis jirovecii pneumonia in renal transplant recipients: a national center experience. Transplant Proc. 2013;45(4):1614–1617. doi:10.1016/j.transproceed.2013.02.10723726632
   PubMed Web of Science ®Google Scholar
• Costa JM, Botterel F, Cabaret O, Foulet F, Cordonnier C, Bretagne S. Association between circulating DNA, serum (1->3)-β-D-glucan, and pulmonary fungal burden in Pneumocystis pneumonia. Clin Infect Dis. 2012;55(2):e5–8. doi:10.1093/cid/cis41222523258
   PubMed Web of Science ®Google Scholar
• Corsi-Vasquez G, Ostrosky-Zeichner L, Pilkington EF, Sax PE, Caliendo AM. Point-counterpoint: should serum β-d glucan testing be used for the diagnosis of Pneumocystis jirovecii pneumonia? J Clin Microbiol. 2019;58(1). doi:10.1128/jcm.01340-19
   Web of Science ®Google Scholar
• de Boer MG, Kroon FP, le Cessie S, de Fijter JW, van Dissel JT. Risk factors for Pneumocystis jirovecii pneumonia in kidney transplant recipients and appraisal of strategies for selective use of chemoprophylaxis. Transpl Infect Dis. 2011;13(6):559–569. doi:10.1111/j.1399-3062.2011.00645.x21689251
   PubMed Web of Science ®Google Scholar
• Muhammad Iqbal AH, Lim SK, Ng KP, Tan LP, Chong YB, Keng TC. Pneumocystis jirovecii pneumonia 13 years post renal transplant following a recurrent cytomegalovirus infection. Transpl Infect Dis. 2012;14(4):E23–E26. doi:10.1111/j.1399-3062.2012.00738.x22551151
   PubMed Web of Science ®Google Scholar
• Martin SI, Fishman JA. Pneumocystis pneumonia in solid organ transplantation. Am J Transplant. 2013;13(Suppl 4):272–279. doi:10.1111/ajt.1211923465020
   PubMed Web of Science ®Google Scholar
• White PL, Price JS, Backx M. Therapy and management of Pneumocystis jirovecii infection. J Fungi (Basel). 2018;4(4). doi:10.3390/jof4040127
   Google Scholar
• Thomas M, Rupali P, Woodhouse A, Ellis-Pegler R. Good outcome with trimethoprim 10 mg/kg/day-sulfamethoxazole 50 mg/kg/day for Pneumocystis jirovecii pneumonia in HIV infected patients. Scand J Infect Dis. 2009;41(11–12):862–868. doi:10.3109/0036554090321425619922070
   PubMed Web of Science ®Google Scholar
• Gabardi S, Millen P, Hurwitz S, Martin S, Roberts K, Chandraker A. Atovaquone versus trimethoprim-sulfamethoxazole as Pneumocystis jirovecii pneumonia prophylaxis following renal transplantation. Clin Transplant. 2012;26(3):E184–190. doi:10.1111/j.1399-0012.2012.01624.x22487221
   PubMed Web of Science ®Google Scholar
• Giullian JA, Cavanaugh K, Schaefer H. Lower risk of urinary tract infection with low-dose trimethoprim/sulfamethoxazole compared to dapsone prophylaxis in older renal transplant patients on a rapid steroid-withdrawal immunosuppression regimen. Clin Transplant. 2010;24(5):636–642. doi:10.1111/j.1399-0012.2009.01129.x19925478
   PubMed Web of Science ®Google Scholar
• Mitsides N, Greenan K, Green D, et al. Complications and outcomes of trimethoprim-sulphamethoxazole as chemoprophylaxis for pneumocystis pneumonia in renal transplant recipients. Nephrology (Carlton). 2014;19(3):157–163. doi:10.1111/nep.1220124387294
   PubMed Web of Science ®Google Scholar
• Aliouat-Denis CM, Martinez A, Aliouat El M, Pottier M, Gantois N, Dei-Cas E. The Pneumocystis life cycle. Mem Inst Oswaldo Cruz. 2009;104(3):419–426. doi:10.1590/s0074-0276200900030000419547866
   PubMed Web of Science ®Google Scholar
• Dei-Cas E. Pneumocystis infections: the iceberg? Med Mycol. 2000;38(Suppl 1):23–32. doi:10.1080/mmy.38.s1.23.32
   PubMed Web of Science ®Google Scholar
• Armstrong-James D, Stebbing J, John L, et al. A trial of caspofungin salvage treatment in PCP pneumonia. Thorax. 2011;66(6):537–538. doi:10.1136/thx.2010.135350
   PubMed Web of Science ®Google Scholar
• Koshy R, Chen T. Combination therapy with trimethoprim-sulfamethoxazole and caspofungin in a case of severe pneumocystis pneumonia. IDCases. 2019;15:e00496. doi:10.1016/j.idcr.2019.e0049630828545
   PubMed Web of Science ®Google Scholar
• Kasiske B, Zeier M, Craig J, et al. KDIGO clinical practice guideline for the care of kidney transplant recipients. Am J Transplant. 2009;9(Suppl 3):S1–155. doi:10.1111/j.1600-6143.2009.02834.x
   Web of Science ®Google Scholar